In May 2023, the U.S. Supreme Court made a ruling in the case of Amgen Inc. v. Sanofi that could reshape the future of antibody claiming in the United States. This pivotal verdict is anticipated to influence enablement and the widely adopted strategy of claiming antibodies on their function. The potential implications of this judgment are yet to be gauged fully, with legal professionals closely monitoring its impact on the pharmaceutical patent landscape.
By November 2023, the courts had begun interpreting the verdict in the context of various pharmaceutical cases. The counts reveal that the Amgen decision has been cited in a total of 17 legal proceedings, inclusive of seven decisions from the Patent Trial and Appeal Board (PTAB), seven cases at the district court level, and three cases at the federal circuit level. Notably, three cases among these featured antibodies as the focal point of their lawsui.
A concise examination of the landmark Amgen v. Sanofi court case and its implications provides an essential understanding of the evolving approach to antibody claims in the United States.